Deutsche Bank AG Reiterates “Buy” Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by stock analysts at Deutsche Bank AG in a report issued on Monday.
Other equities research analysts have also recently issued reports about the company. Liberum Capital reaffirmed a “buy” rating and set a GBX 5,200 ($67.65) price objective on shares of AstraZeneca plc in a research report on Tuesday, January 31st. Jefferies Group LLC dropped their price objective on AstraZeneca plc from GBX 5,400 ($70.25) to GBX 4,800 ($62.44) and set a “buy” rating on the stock in a research report on Monday, January 30th. Kepler Capital Markets reaffirmed a “buy” rating and set a GBX 5,000 ($65.04) price objective on shares of AstraZeneca plc in a research report on Monday, January 23rd. Berenberg Bank dropped their price objective on AstraZeneca plc from GBX 5,500 ($71.55) to GBX 5,450 ($70.90) and set a “buy” rating on the stock in a research report on Tuesday, February 21st. Finally, Bryan, Garnier & Co reaffirmed a “buy” rating and set a GBX 5,400 ($70.25) price objective on shares of AstraZeneca plc in a research report on Tuesday, February 28th. Five research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of GBX 5,001.80 ($65.07).
AstraZeneca plc (LON:AZN) traded up 0.21% during trading on Monday, reaching GBX 5130.00. 2,188,205 shares of the company’s stock were exchanged. The firm has a 50 day moving average of GBX 4,804.10 and a 200-day moving average of GBX 4,565.16. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The stock’s market cap is GBX 64.95 billion.
ILLEGAL ACTIVITY NOTICE: “Deutsche Bank AG Reiterates “Buy” Rating for AstraZeneca plc (AZN)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/05/22/deutsche-bank-ag-reiterates-buy-rating-for-astrazeneca-plc-azn.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.